Course Introduction

COURSE OVERVIEW
This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials using new drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.

There was a fundamental change in the treatment of chronic hepatitis C in late 2014 with the addition of multiple new direct-acting antiviral (DAAs) drugs to current standard of care for all genotypes. There will be two separate lectures devoted to this topic this year. The first will be on currently available all-oral therapies that have been approved and are currently in use. The second will be on future therapies that will shorten duration and lower cost of a cure. In addition, the pre-conference will extensively detail currently available treatment regimens with the goal of introducing the topic to new treaters.

The landscape of hepatitis C has been profoundly changed by the development of IFN-free DAA therapies. Our major challenge now is to identify those who are infected and get them treated. To this end, we have invited John Ward, MD, Director of the Viral Hepatitis Program, Division of Viral Hepatitis at the National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention to speak as the William S. Haubrick Memorial Lecturer this year.

In hepatitis B, the treatments have not changed but there is more mature data available on long-term HBsAg loss and clinical outcomes. The addition of immune-mediated therapies for HBV with the goal of curing the disease has been included in this year’s program. New therapies for NAFLD and NASH are in development and important new data showing positive results in NASH will be presented at this meeting. The explosive growth of NASH in the US has created a significant need for effective drug therapy. The diagnosis and treatment of hepatocellular carcinoma will be updated as this disease is one of the few cancers with a growing incidence in the US. New oral therapy is moving this field forward. There will be an update on management of hepatic encephalopathy, hyponatremia and the management of complications in the transplant candidate.

EDUCATIONAL OBJECTIVES
After attending this live activity, participants should be able to:
- Detail the AASLD guidelines for treatment of HCV using DAAs in IFN-free regimens.
- Review our current knowledge of NAFLD and non-alcoholic steatohepatitis and explore the use of new agents and approaches to treatment of the conditions.
- Integrate the algorithm for a therapeutic approach to treatment of HBV using anti-virals.
- Discuss therapies for HCV including NS5A, protease and polymerase inhibitors.
- Update the skills and management required for transplant hepatology.
- Apply current options of therapy for hepatocellular carcinoma to determine the best approach for your patients.
- Discuss future treatment paradigms for HCV direct-acting anti-viral drug.
- Describe the diagnosis and treatment of PBC and PSC.
- Integrate treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorder.
- Discuss the issues complicating drug treatment in decompensated cirrhosis, hepatic encephalopathy and hyponatremia.
- Review the diagnosis and management of DILI.

ACCRREDITATION
Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Scripps Health designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit Breakdown:
Pre-Conference (Fri): 3.5
Main Conference (Sat-Sun): 10

American Academy of Physician Assistants (AAPA)
The American Academy of Physician Assistants (AAPA) accepts Category 1 credit from AMA PRA Category 1 CME organizations accredited by the ACCME.

Board of Registered Nursing (BRN)
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit(s)™ issued by organizations accredited by the ACCME. For the purpose of re-licensure, the California Board of Registered Nursing accepts AMA PRA Category 1 Credit(s)™. The majority of state boards accept AMA PRA Category 1 Credit(s)™ as meeting continuing education requirements for license renewal. Nurses should check with their state’s Board of Registered Nursing regarding use of CME credit.

EDUCATIONAL GRANTS
This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. Appropriate acknowledgement will be given to all supporters at the time of the educational activity.
We will review the virology, genotypes, modes of infection of HCV and characteristics of the clinical illness caused by acute and chronic infections. Tests for HCV, including PCR assays and genotyping, interpretations and indications for liver biopsies and complications of cirrhosis will also be discussed. We will show how to initiate and monitor patients during treatment with multiple anti-viral oral regimens, how to manage side effects of therapy and deal with various patient populations including HIV-coinfected, CKD on hemodialysis and ESLD patients. Lastly, the AASLD/IDSA Guidelines will be reviewed.

PRE-CONFERENCE
Friday, March 31, 2017
12:30 p.m. Registration
1 p.m. Welcome & Introduction
   Paul Pockros, MD
1:10 p.m. Update on HCV Diagnostics
   Paul Pockros, MD
1:40 p.m. Update on Current Therapy with All-Oral Regimens
   Paul Pockros, MD
2:40 p.m. Break & View Exhibits
3 p.m. Cirrhosis and Post-Transplant
   Catherine Frenette, MD
3:30 p.m. Case Presentation, Discussion and Q&A
   • Selection of Treatment
   • Cirrhosis: Who to Treat
   • Special Populations
   Yuki Rosenkoetter, PA-C, MPAS
5 p.m. Adjourn

DISCLOSURES

Faculty Disclosure
In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

A complete listing of disclosures associated with this program can be found on the conference website: www.scripps.org/livercme and in the mobile conference app: www.grupio.com/Liver17
MA IN C ONFERENCE
Saturday, April 1, 2017

7:30 a.m. Registration, Breakfast & View Exhibits

8 a.m. Welcome & Introduction
Paul Pockros, MD

CHRONIC VIRAL HEPATITIS
Moderator: Paul Pockros, MD

8:15 a.m. WILLIAM S HAUBRICH MEMORIAL LECTURE
Epidemiology, Demographics, Screening
John Ward, MD

9 a.m. Current Standards of Care, HCV
Norah Terrault, MD

9:30 a.m. HBV: March To Cure
Robert Gish, MD

10 a.m. Break & View Exhibits

10:15 a.m. Future Therapies
Paul Pockros, MD

DEBATE
11 a.m. We Should Treat DAA Failures with Medications We Have Now
Norah Terrault, MD

11:05 a.m. DAA Failures Should Not Be Treated Until New Medications Are Available
Paul Pockros, MD

11:10 a.m. Panel Discussion
Robert Gish, MD
Paul Pockros, MD
Norah Terrault, MD and
John Ward, MD

11:45 a.m. Lunch

NASH, ALD, DILI
Moderator: Catherine Frenette, MD

1 p.m. Alcoholic Hepatitis and ALD
Timothy Morgan, MD

1:45 p.m. NAFLD/NASH
Steven Harrison, MD

2:30 p.m. Break & View Exhibits

3 p.m. DILI
Norman Sussman, MD

DEBATE
3:45 p.m. Alcoholic Hepatitis Patients Should Be Treated With Liver Transplant
Timothy Morgan, MD

3:50 p.m. Alcoholic Hepatitis Patients Should Not Be Considered For Liver Transplant
Steven Harrison, MD

4 p.m. Panel Discussion
Steven Harrison, MD
Timothy Morgan, MD and
Norman Sussman, MD

4:30 p.m. Adjourn

Sunday, April 2, 2017

7:30 a.m. Breakfast & View Exhibits

ESLD, TRANSPLANTATION, HCC
Moderator: Paul Pockros, MD

8 a.m. Management of PBC with use of OCA in ESLD for 2017
Norman Sussman, MD

8:45 a.m. OTLX and HCV Treatment
Tram Tran, MD

9:30 a.m. HCC
Catherine Frenette, MD

10:15 a.m. Break & View Exhibits

DEBATE
10:30 a.m. Is There Really an Increased Risk for Recurrent HCC after DAA-SVR: Yes
Tram Tran, MD

10:35 a.m. Is There Really an Increased Risk for Recurrent HCC after DAA-SVR: No
Catherine Frenette, MD

11 a.m. Panel Discussion
Catherine Frenette, MD
Norman Sussman, MD and
Tram Tran, MD

11:45 a.m. Adjournment
Conference Fees & Registration

PRE-CONFERENCE FEES
Included: Course tuition, access to conference materials (via mobile app and conference website) and internet in meeting space.

Not Included: Printed course syllabus, meals, travel costs, parking and lodging.

<table>
<thead>
<tr>
<th></th>
<th>Thru Feb 27</th>
<th>Feb 27 - Mar 27</th>
<th>On-site after Mar 27</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-conference</td>
<td>$100</td>
<td>$125</td>
<td>$150</td>
</tr>
</tbody>
</table>

MAIN CONFERENCE FEES
Included: Course tuition, access to conference materials (via mobile app and conference website), internet in meeting space, breakfasts, breaks and lunch.

Not Included: Printed course syllabus, travel costs, parking, lodging and dinners.

Please note: there are no day rates available for this conference.

<table>
<thead>
<tr>
<th></th>
<th>Thru Feb 27</th>
<th>Feb 27 - Mar 27</th>
<th>On-site after Mar 27</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>$305</td>
<td>$330</td>
<td>$355</td>
</tr>
<tr>
<td>Non-Physician</td>
<td>$235</td>
<td>$260</td>
<td>$285</td>
</tr>
<tr>
<td>Fellows and Residents</td>
<td>$165</td>
<td>$190</td>
<td>$215</td>
</tr>
</tbody>
</table>

CONFERENCE COURSE MATERIALS
Access to Conference App (included in cost of pre and main conference fees) $100

TO REGISTER
Online: www.scripps.org/livercme

ATTENDANCE POLICIES
Attendee Cancellation, Substitution, Refund
The course tuition is refundable, minus a $100 processing fee for the main conference ($40 for Fellows and Residents) and $20 processing fee for the pre-conference if your cancellation is received in writing no later than March 22, 2017. Attendee substitutions are allowed, but notification must be made in writing by March 22, 2017. After this date, under no circumstances will refunds, credits, or substitutions be granted. No refunds or credits will be given to “no shows.”

Scripps Conference Modification or Cancellation
Scripps reserves the right to modify the course’s schedule or program as necessary. Scripps also reserves the right to cancel this conference, in which case a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of Scripps cancellation.

Conference Location

ESTANCIA LA JOLLA HOTEL
9700 N. Torrey Pines Road, La Jolla, California 92037  •  855-318-7602  •  estancialajolla.com

Please make your own sleeping room reservation, no later than March 13, 2017. Mention you are with the Scripps Liver Disease conference to receive the reduced rate of $229 per night, discounted after $15 hospitality service fee.

Download the Scripps CME App
All conference information, including a detailed agenda, faculty listing, faculty disclosures, industry support, attendee list, and course materials can be found on the free Scripps CME conference app for smart phones, tablets and laptop computers. To download the app on your smart phone or other device visit the appropriate app store and search ScrippsCME (must be one word). The app is free of charge and will be continuously updated during and after the course.

To access the site using a web browser: http://www.grupio.com/livercme
New Treatments in Chronic Liver Disease

MARCH 31 - APRIL 2, 2017

2017 CONFERENCE HIGHLIGHTS

• Conference presentations will be available via mobile app and conference website. Internet will be available in the meeting space.
• Half Day Pre-Conference Seminar reviewing the virology, genotypes and modes of infection of HCV.
• Comprehensive presentations of the latest advances in hepatology with renowned faculty chosen for their expertise as well as teaching skills.
• Attendees will have opportunities to network with each other and interact with speakers to discuss topics from the course.

TARGET AUDIENCE

Hepatologists
Gastroenterologists
Infectious Disease Specialists
Nurse Practitioners

Physician Assistants
Nurses
Residents/Fellows
and others desiring an update in these specialty areas